What is aTyr Pharma, Inc. Common Stock's Market Cap?

aTyr Pharma, Inc. Common Stock's Market Cap is $47.2M, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's Enterprise Value?

aTyr Pharma, Inc. Common Stock's Enterprise Value is $31.6M, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's Price / Sales?

aTyr Pharma, Inc. Common Stock's Price / Sales is 248.2×, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's EV / Revenue?

aTyr Pharma, Inc. Common Stock's EV / Revenue is 166.1×, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's EV / EBITDA?

aTyr Pharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's Revenue (TTM)?

aTyr Pharma, Inc. Common Stock's Revenue (TTM) is $190.0K, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's Net Income (TTM)?

aTyr Pharma, Inc. Common Stock's Net Income (TTM) is -$60.8M, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's EBITDA?

aTyr Pharma, Inc. Common Stock's EBITDA is -$63.2M, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's Diluted EPS (TTM)?

aTyr Pharma, Inc. Common Stock's Diluted EPS (TTM) is -0.62, based on as-reported figures from SEC (XBRL) filings.

What is aTyr Pharma, Inc. Common Stock's EBITDA Margin?

aTyr Pharma, Inc. Common Stock's EBITDA Margin is -33261.6%, based on as-reported figures from SEC (XBRL) filings.

aTyr Pharma, Inc. Common Stock (ATYR) Financial Statements

aTyr Pharma, Inc. Common Stock

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG001V0GF01

XNAS · usd

0.48▼ 0.02 (-3.32%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close0.50

Day's Range0.48 – 0.51

52-Week Range0.40 – 6.50

Volume631.1K

Avg Volume617.6K

Share Statistics

Shares Outstanding

Employees58

ExchangeXNAS

Listed2015-05-07

Share count as of July 31, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about aTyr Pharma, Inc. Common Stock (ATYR)

What is aTyr Pharma, Inc. Common Stock's Market Cap?: aTyr Pharma, Inc. Common Stock's Market Cap is $47.2M, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's Enterprise Value?: aTyr Pharma, Inc. Common Stock's Enterprise Value is $31.6M, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's Price / Sales?: aTyr Pharma, Inc. Common Stock's Price / Sales is 248.2×, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's EV / Revenue?: aTyr Pharma, Inc. Common Stock's EV / Revenue is 166.1×, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's EV / EBITDA?: aTyr Pharma, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's Revenue (TTM)?: aTyr Pharma, Inc. Common Stock's Revenue (TTM) is $190.0K, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's Net Income (TTM)?: aTyr Pharma, Inc. Common Stock's Net Income (TTM) is -$60.8M, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's EBITDA?: aTyr Pharma, Inc. Common Stock's EBITDA is -$63.2M, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's Diluted EPS (TTM)?: aTyr Pharma, Inc. Common Stock's Diluted EPS (TTM) is -0.62, based on as-reported figures from SEC (XBRL) filings.
What is aTyr Pharma, Inc. Common Stock's EBITDA Margin?: aTyr Pharma, Inc. Common Stock's EBITDA Margin is -33261.6%, based on as-reported figures from SEC (XBRL) filings.